Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Warren Fiskus, Christopher P. Mill, Christine Birdwell, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Michael Collins, et al.
Blood (2024) Vol. 143, Iss. 20, pp. 2059-2072
Open Access | Times Cited: 18
CGMega: explainable graph neural network framework with attention mechanisms for cancer gene module dissection
Hao Li, Zebei Han, Yu Sun, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Omics approaches: Role in acute myeloid leukemia biomarker discovery and therapy
Fatemeh Sadat Shafiei, Saeid Abroun, Sadaf Vahdat, et al.
Cancer Genetics (2025) Vol. 292-293, pp. 14-26
Closed Access | Times Cited: 1
Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia
Xinyue Zhou, Lixia Zhang, Sajesan Aryal, et al.
Blood (2024) Vol. 144, Iss. 19, pp. 2018-2032
Open Access | Times Cited: 6
Advances in acute myeloid leukemia differentiation therapy: A critical review
Amal Kamal Abdel‐Aziz
Biochemical Pharmacology (2023) Vol. 215, pp. 115709-115709
Closed Access | Times Cited: 14
Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI‐503 against MLL::AF9‐driven acute myeloid leukaemia
Wenqi Zhu, Yiyi Ding, Wanling Huang, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 2, pp. 568-579
Closed Access | Times Cited: 5
Revumenib: First Approval
Yahiya Y. Syed
Drugs (2025)
Closed Access
Menin: from molecular insights to clinical impact
Margaret R. Brown, Yadira M. Soto-Feliciano
Epigenomics (2025), pp. 1-17
Open Access
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation
Maximilian Fleischmann, Julia Bechwar, Diana Voigtländer, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1311-1311
Open Access | Times Cited: 4
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
Branko Cuglievan, Hagop M. Kantarjian, Jeffrey E. Rubnitz, et al.
Leukemia (2024) Vol. 38, Iss. 10, pp. 2073-2084
Open Access | Times Cited: 4
Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, et al.
International Journal of Cancer (2025)
Open Access
The future of HOXA-expressing leukemias: Menin inhibitor response and resistance
Daniela V. Wenge, Scott A. Armstrong
Current Opinion in Hematology (2023) Vol. 31, Iss. 2, pp. 64-70
Closed Access | Times Cited: 7
Flow cytometry in acute myeloid leukemia and detection of minimal residual disease
Qihui Cai, Haiqiang Lan, Yi Deng, et al.
Clinica Chimica Acta (2024) Vol. 564, pp. 119945-119945
Open Access | Times Cited: 2
Menin in Cancer
Ariana D. Majer, Xianxin Hua, Bryson W. Katona
Genes (2024) Vol. 15, Iss. 9, pp. 1231-1231
Open Access | Times Cited: 2
Dependency of B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma Cell Lines on MEN1 Extends beyond MEN1–KMT2A Interaction
Tatjana Magdalena Wolffhardt, Franz Ketzer, Stefano Telese, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 22, pp. 16472-16472
Open Access | Times Cited: 5
Acute Myeloid Leukemia Genomics: Impact on Care and Remaining Challenges
Ann‐Kathrin Eisfeld, Elaine R. Mardis
Clinical Chemistry (2024) Vol. 70, Iss. 1, pp. 4-12
Closed Access | Times Cited: 1
Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM)
Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions
Sandhya Dhiman, Vikram Dhillon, Suresh Kumar Balasubramanian
Cancers (2024) Vol. 16, Iss. 22, pp. 3743-3743
Open Access | Times Cited: 1
Targeting chromatin modifying complexes in acute myeloid leukemia
Alexandra Schurer, Shira Glushakow-Smith, Kira Gritsman
Stem Cells Translational Medicine (2024)
Open Access | Times Cited: 1
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Mathew Sheridan, Muhammad Ahmad Maqbool, Anne Largeot, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access
Single-Cell Atlas of AML Reveals Age-Related Gene Regulatory Networks in t(8;21) AML
Jessica S. Whittle, Stefan Meyer, Georges Lacaud, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Broken brakes: PRC loss foils menin inhibition
Nahal Azimi, Aniruddha J. Deshpande
Blood (2024) Vol. 144, Iss. 19, pp. 1979-1980
Closed Access
Synergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor
Sandra Cantilena, Mohamed Salem Alameri, Noélia Che, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4017-4017
Open Access
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor
Warren Fiskus, Jessica Piel, Mike Collins, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top